• #1181586
  • Alnylam Pharmaceuticals Inc #71336100201

Oxlumo® Lumasiran Injection Single-Dose Vial

OXLUMO, VL 94.5MG/0.5ML D/S

Alnylam Pharmaceuticals Inc 71336100201
Oxlumo® Lumasiran Injection Single-Dose Vial
Compare
Features
  • OXLUMO® is an HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of Primary Hyperoxaluria Type 1 (PH1) to lower the urinary oxalate levels in pediatric and adult patients. PH1 is an ultra-rare progressive genetic disease that can be potentially life-threatening.
  • More …
  Log In to Order
or
 View Alternatives

Product Specifications

Features
  • OXLUMO® is an HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of Primary Hyperoxaluria Type 1 (PH1) to lower the urinary oxalate levels in pediatric and adult patients. PH1 is an ultra-rare progressive genetic disease that can be potentially life-threatening.
Compare Products (0) Clear Compare